Open Access

AGR3 promotes estrogen receptor‑positive breast cancer cell proliferation in an estrogen‑dependent manner

  • Authors:
    • Lei Jian
    • Jian Xie
    • Shipeng Guo
    • Haochen Yu
    • Rui Chen
    • Kai  Tao
    • Chengcheng Yang
    • Kang Li
    • Shengchun Liu
  • View Affiliations

  • Published online on: May 28, 2020     https://doi.org/10.3892/ol.2020.11683
  • Pages: 1441-1451
  • Copyright: © Jian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is one of the most common malignancies and the leading cause of cancer‑associated death among women. Anterior gradient 3 (AGR3) is a cancer‑associated gene and is similar to its homologous oncogene AGR2. However, whether AGR3 participates in breast cancer progression remains unclear. The present study aimed to investigate the function of AGR3 in ER‑positive breast cancer. In the present study, reverse transcription‑quantitative PCR was used to detect AGR3 mRNA expression in breast cancer tissues and cell lines; linear correlation analysis was used to investigate the correlation between AGR3 and estrogen receptor 1 (ESR1) expression in breast cancer via GEO dataset analysis; western blotting was used to assess the levels of AGR3, ER and GAPDH; small interfering (si)RNA transfection was used to knock down AGR3 and ESR1 expression; and finally the Cell Counting Kit‑8 assay was used to evaluate cell viability. In the present study, AGR3 expression was markedly increased in estrogen receptor (ER)‑positive breast cancer tissues and cell lines compared with that in ER‑negative breast cancer. AGR3 expression was upregulated in estrogen‑treated T47D cells, whereas 4‑hydroxytamoxifen, an inhibitor of estrogen‑ER activity in breast cancer cells, downregulated AGR3 expression in T47D cells. Functional assays demonstrated that knockdown of AGR3 using siRNAs inhibited T47D cell proliferation compared with that of the negative control group. Additionally, AGR3 expression was decreased after knocking down ESR1. The present results suggested that AGR3 may serve an important role in estrogen‑mediated cell proliferation in breast cancer and that AGR3 knockdown may be a potential therapeutic strategy for ER‑positive breast cancer.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Jian, L., Xie, J., Guo, S., Yu, H., Chen, R., Tao, K. ... Liu, S. (2020). AGR3 promotes estrogen receptor‑positive breast cancer cell proliferation in an estrogen‑dependent manner. Oncology Letters, 20, 1441-1451. https://doi.org/10.3892/ol.2020.11683
MLA
Jian, L., Xie, J., Guo, S., Yu, H., Chen, R., Tao, K., Yang, C., Li, K., Liu, S."AGR3 promotes estrogen receptor‑positive breast cancer cell proliferation in an estrogen‑dependent manner". Oncology Letters 20.2 (2020): 1441-1451.
Chicago
Jian, L., Xie, J., Guo, S., Yu, H., Chen, R., Tao, K., Yang, C., Li, K., Liu, S."AGR3 promotes estrogen receptor‑positive breast cancer cell proliferation in an estrogen‑dependent manner". Oncology Letters 20, no. 2 (2020): 1441-1451. https://doi.org/10.3892/ol.2020.11683